Moderna co-founder Noubar Afeyan is calling for strict safety regulations on commercial AI agents before they are released to the public.
Moderna shares have surged 663% in 2026, making it the best-performing stock in the S&P 500 following positive clinical trial results for its experimental cancer vaccine.
Moderna and Merck have reported positive Phase 3 results for an AI-driven, personalized cancer vaccine, marking a milestone in individualized medicine.
Personalized cancer vaccines from Moderna and Merck have boosted drugmakers' market value by over $50 billion, opening new investment paths in genomic sequencing diagnostics.
